New approaches for mesothelioma: Biologics, vaccines, gene therapy, and other novel agents

Seminars in Oncology

Volumn 29, Issue 1, 2002, Pages 82-96

  Nowak, Anna K ^a,b   Lake, Richard A ^a,b   Kindler, Hedy Lee ^a,b   Robinson, Bruce W S ^a,b,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF CHICAGO   (United States)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ADHSV-TK; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ASBESTOS; B7 ANTIGEN; BCG VACCINE; BEVACIZUMAB; CANCER VACCINE; CD86 ANTIGEN; GAMMA INTERFERON; GANCICLOVIR; GEFITINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 65; IMATINIB; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; METHOTREXATE; PHOSPHORYL LIPID A; PROTEIN TYROSINE KINASE; QS 21; SEMAXANIB; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA VACCINE; VIRUS PROTEIN; VIRUS T ANTIGEN; VIRUS VECTOR;

CLINICAL TRIAL; DRUG POTENTIATION; FEVER; FLU LIKE SYNDROME; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; LIVER TOXICITY; LYMPHOKINE ACTIVATED KILLER CELL; MESOTHELIOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUICIDE GENE THERAPY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VACCINIA VIRUS;

EID: 0036178251     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.30234     Document Type: Article

References (103)

1. Wittenoom, Western Australia: A modern industrial disaster
2. Lymphocytic infiltration of pleural mesothelioma and its significance for survival
3. Localised spontaneous mesothelioma regression - Possible immunological mechanism
4. Mesothelioma: Recent studies of growth regulation
5. Lymphocyte responses to phytohaemagglutinin in patients with asbestosis and pleural mesothelioma
6. Asbestos fibres inhibit the in vitro activity of lymphokine-activated killer (LAK) cells from healthy individuals and patients with malignant mesothelioma
7. High frequency of immune dysfunctions in asbestos workers and in patients with malignant mesothelioma
8. Molecular pathobiology and immunology of malignant mesothelioma
9. Asbestos and cancer: Human natural killer cell activity is suppressed by asbestos fibres but can be restored by recombinant interleukin 2
10. Immunotherapy with BCG vaccine in 30 cases of mesothelioma
11. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes
12. Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells
13. Intralesional cytokine therapy in cancer: A pilot study of GM-CSF infusion in mesothelioma
14. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation
15. Malignant mesothelioma: The antiproliferative effect of cytokine combinations on three human mesothelioma cell lines
16. Chemosensitivity and cytokine sensitivity of malignant mesothelioma
17. Comparative studies of human malignant mesothelioma in vivo, in xenografts in nude mice, and in vitro. Cell origin of malignant mesothelioma
18. Potential for interferon-alpha-based therapy in mesothelioma: Assessment in a murine model
19. Interferon (IFN)-alpha and IFN-gamma in combination with methotrexate: In vitro sensitivity studies in four human mesothelioma cell lines
20. HLA antigen expression and malignant mesothelioma
21. Effect of recombinant interferon-beta ser on primary human tumor colony-forming units
22. Intrapleural treatment with recombinant gamma interferon in early stage malignant pleural mesothelioma
23. Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro
24. Interleukin 2 and lymphokine activated killer cells in malignant mesothelioma
25. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: A phase II study
26. Interleukin-12 induces an effective antitumor response in malignant mesothelioma
27. Recombinant human interleukin-12 (rhIL-12) in patients with ovarian and gastrointestinal cancers. Evidence of biological activity and lack of significant toxicity with low-dose intraperitoneal (ip) administration
28. Effects of single-dose interleukin-12 (IL-12) exposure on IL-12 on IL-12 associated toxicity and interferon-γ production
29. Capacity of tumor necrosis factor to augment lymphocyte-mediated tumor cell lysis of malignant mesothelioma
30. Phase I evaluation of recombinant tumor necrosis factor given in combination with recombinant interferon-gamma
31. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
32. Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen
33. Genetic alterations of the p53 gene are a feature of malignant mesotheliomas
34. Analysis of K-ras and p53 mutations in mesotheliomas from humans and rats exposed to asbestos
35. Mutations of p53 gene and SV40 sequences in asbestos associated and nonasbestos-associated mesotheliomas
36. Absence of p53 mutations in malignant mesotheliomas
37. P53 autoantibodies in patients with malignant mesothelioma: Stability through disease progression
38. Serologic responses in patients with malignant mesothelioma: Evidence for both public and private specificities
39. Tumor antigens are constitutively presented in the draining lymph nodes
40. Cross-presentation of tumour antigens: Evaluation of threshold, duration, distribution and regulation
41. Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesothelioma
42. Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions
43. An innate sense of danger
44. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy
45. The treatment of malignant mesothelioma with a gene modified cancer cell line: A phase I study
46. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma
47. Characterization of the rat neurofibromatosis 2 gene and its involvement in asbestos-induced mesothelioma
48. Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: Evidence for a two-hit mechanism of NF2 inactivation
49. Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression
50. Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells
51. Antiviral activity and mechanism of action of ganciclovir
52. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma
53. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer
54. Advances in the treatment of malignant pleural mesothelioma
55. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma
56. Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy
57. The induction of immune responses to murine malignant mesothelioma by 1L-2 gene transfer
58. Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12
59. The immune anti-tumor effects of B7-1 gene transfection are enhanced by surgical debulking of tumor
60. Heat shock proteins in cancer therapy
61. Antitumor activity with the HSV-tk-gene-modified cell line PA-1-STK in malignant mesothelioma
62. Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma
63. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
64. The Toll receptor family and microbial recognition
65. Paracrine cytokine adjuvants in cancer immunotherapy
66. Cancer vaccines
67. Immunotherapy of metastases enhances subsequent chemotherapy
68. Interferon alpha and doxorubicin in malignant mesothelioma: A phase II study
69. Augmentation of activity of cis-diamminedichloroplatinum(II) and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice
70. Cisplatin, mitomycin, and interferon-alpha 2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma
71. Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a
72. Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma
73. Combination raltitrexed (Tomudex)-oxaliplatin: A step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma
74. A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma
75. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable nonsmall-cell lung cancer and mesothelioma
76. VEGF, VEGF type C, and their receptors play an important role in angiogenesis and lymphangiogensis in human malignant mesothelioma tumors
77. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
78. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) inpatients with carcinoma and sarcoma
79. Serum levels of b-FGF and FGF in patients with metastatic solid tumors
80. Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma
81. Evaluation of tumor angiogenesis as a prognostic marker in malignant mesothelioma
82. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
83. SU5416 in malignant mesothelioma: A University of Chicago phase II consortium study
84. The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice
85. Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian, and breast cancer
86. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor-selective tyrosine kinase inhibitor
87. EGFR and HER-2 overexpression in malignant mesothelioma
88. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4 monoclonal antibody
89. Autocrine stimulation of a human lung mesothelioma cell line is mediated through the transforming growth factor alpha/epidermal growth factor receptor mitogenic pathway
90. Inhibition of the epidermal growth factor receptor family of the tyrosine kinases as an approach to cancer chemotherapy: Progression from reversible to irreversible inhibitors
91. Differential expression of platelet-derived growth factor-beta in malignant mesothelioma: A clue to future therapies?
92. Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo
93. Comparison of production of transforming growth factor-beta and platelet derived growth factor by normal human mesothelial cells and mesothelioma cell lines
94. Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha receptors
95. Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme
96. Abl protein tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet derived growth factor receptors
97. Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma
98. Effect of interferon-alpha 2a on malignant mesothelioma
99. Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: A Southwest Oncology Group study
100. Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion
101. Intrapleural administration of interleukin 2 in pleural mesothelioma: A phase I-II study
102. Treatment of three patients with malignant mesothelioma with the gene modified cell line PA1-STK